Novo-Nordisk stock: Oddo BHF raises target to DKK 305 for Novo-Nordisk stock

Published on 10/21/2026 at 15:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UBS held a DKK 332.00 target on October 14, 2026. Novo-Nordisk stock costs EUR 34.91 on October 21, 2026, plus 0.20 percent versus the Xetra close.

Analyst targets reset

Oddo BHF raised its Novo Nordisk target from DKK 221.00 to DKK 305.00 on October 20, 2026.
UBS retained a DKK 332.00 target and Neutral rating on October 14, 2026.
Novo-Nordisk stock costs EUR 34.91 at Lang & Schwarz on October 21, 2026 at 3:34 p.m. CEST, 0.20 percent above the Xetra close of October 20, 2026.

Flatlay mit Spritze, Teststreifen, Notizbuch und Apfel auf weißem Untergrund — Novo Nordisk A/S (DK0062498333): Flatlay mit Spritze, Blutzucker-Teststreifen, Notizbuch und Apfel auf Weiß, Illustration mit AI erstellt.

Novo Nordisk (ISIN DK0062498333) faces a higher valuation hurdle after Oddo BHF raised its price target from DKK 221.00 to DKK 305.00 on October 20, 2026, while reiterating a Neutral rating, according to MarketScreener. At Lang & Schwarz, the stock was trading at EUR 34.91 on October 21, 2026 at 3:34 p.m. CEST, 0.20 percent above the Xetra close of October 20, 2026 at EUR 34.84.

Analyst targets move closer

Oddo BHF's new target implies 18.91 percent upside from Novo Nordisk's DKK 256.50 close on Nasdaq Copenhagen on October 19, 2026. The target change is notable because the firm still kept its Neutral stance rather than turning the higher valuation into a positive recommendation.

UBS also kept a Neutral rating and a DKK 332.00 target in a study dated October 14, 2026, according to Der Aktionär. That target stands 29.43 percent above the same DKK 256.50 reference price, leaving the two recent targets above the latest Copenhagen close.

First-half figures frame the debate

Novo Nordisk reported adjusted first-half 2026 sales of DKK 148.60 billion and adjusted operating profit of DKK 66.20 billion, both up 2.00 percent at constant exchange rates, according to Dividend-Line. The second-quarter adjusted operating profit was DKK 33.40 billion, up 11.00 percent at constant exchange rates, giving investors a recent operating comparison alongside the target revisions.

November 4 is the next date

MarketBeat estimates that Novo Nordisk will report third-quarter 2026 results on November 4, 2026, with the earnings call scheduled for 7:00 a.m. ET, according to MarketBeat. The same page lists a consensus revenue estimate of USD 11.15 billion and consensus earnings per share of USD 0.7420 for the quarter, versus USD 11.79 billion and USD 1.02 in the year-earlier quarter.

The euro quote stays near EUR 35

The Lang & Schwarz price was EUR 34.91, just above the EUR 34.84 Xetra close of October 20, 2026. The small daily difference leaves the analyst targets and the November reporting date as the stronger reference points for the stock's current valuation discussion.

Novo Nordisk is listed on Nasdaq Copenhagen under the NOVO B share and is also quoted on Xetra under the symbol NOV. The company is classified in the pharmaceuticals industry.